WithdrawnPhase 1/2

Intervention of Engineered Immune Effector T Cells Against Lung Cancer

Stopped: combine with NCT03356808

China0Started 2017-11-15

Plain-language summary

The primary objective of this study is to evaluate the safety of lung cancer specific cytotoxic lymphocytes (LC-CTLs). The secondary objectives are to evaluate the rate of successful LC-CTLs generation in vitro and determine the anti-lung cancer efficacy.

Who can participate

Age range

18 Years – 70 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Written, informed consent obtained prior to any study-specific procedures.
. Age older than 18 years.
. Patients with refractory, relapsed, metastatic, advanced lung cancer confirmed by histology and biopsy.
. Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
. Expected survival ≥ 12 weeks.
. Not pregnant, and on appropriate birth control if of childbearing potential.
. Initial hematopoietic reconstitution with
. Proper renal and hepatic functions (ULN denotes "upper limit of normal range") with

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Safety of LC-CTLs in patients using CTCAE version 4.0 standard to evaluate the level of adverse events

Timeframe: 3 months

Trial details

NCT IDNCT03353428

SponsorShenzhen Geno-Immune Medical Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-01

View on ClinicalTrials.gov More Lung Cancer trials

Who can participate

Age range

18 Years – 70 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Written, informed consent obtained prior to any study-specific procedures.
. Age older than 18 years.
. Patients with refractory, relapsed, metastatic, advanced lung cancer confirmed by histology and biopsy.
. Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
. Expected survival ≥ 12 weeks.
. Not pregnant, and on appropriate birth control if of childbearing potential.
. Initial hematopoietic reconstitution with
. Proper renal and hepatic functions (ULN denotes "upper limit of normal range") with

Intervention of Engineered Immune Effector T Cells Against Lung Cancer

Plain-language summary

Who can participate

Inclusion criteria

Questions worth asking your doctor

Questions for the trial coordinator

What they're measuring

Trial details

Intervention of Engineered Immune Effector T Cells Against Lung Cancer

Plain-language summary

Who can participate

Inclusion criteria

Questions worth asking your doctor

Questions for the trial coordinator

What they're measuring

Trial details

Exclusion criteria